Celastrol and Resveratrol Modulate Genes Expression and Exert Anticancer Activity in Colon Cancer Cells and Cancer Stem-like Cells.

Fiche publication

Date publication

mars 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MULLER Christian

Tous les auteurs :
Moreira H, Szyjka A, Grzesik J, Pelc K, Żuk M, Kulma A, Emhemmed F, Muller CD, Gąsiorowski K, Barg E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35326523

Résumé

Metastatic colorectal cancer (CRC) remains a hard-to-cure neoplasm worldwide. Its curability declines with successive lines of treatment due to the development of various cancer resistance mechanisms and the presence of colorectal cancer stem cells (CSCs). Celastrol and resveratrol are very promising phytochemicals for colon cancer therapy, owing to their pleiotropic activity that enables them to interact with various biological targets. In the present study, the anticancer activities of both compounds were investigated in metastatic colon cancer cells (LoVo cells) and cancer stem-like cells (LoVo/DX). We showed that celastrol is a very potent anti-tumor compound against metastatic colon cancer, capable of attenuating CSC-like cells at the molecular and cellular levels. In contrast, resveratrol has a much greater effect on colon cancer cells that are expressing standard sensitivity to anticancer drugs, than on CSC-like cells. In addition, both polyphenols have different influences on the expression of genes, which seems to be at least partly related to their anti-tumor activity.